Antônio Miguel Furtado Leitão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antônio Miguel Furtado Leitão has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Francisco de Assis Aquino Gondim
Universidade Federal do Ceará, Faculdade de Medicina, Fortaleza CE, Brazil
8 shared publications - Florian Patrick Thomas
Hackensack Meridian School of Medicine
3 shared publications - Lucia Libanez Bessa Campelo Braga
Universidade Federal do Ceará, Faculdade de Medicina, Departamento de Medicina Clínica, Serviço de Gastroenterologia, Fortaleza CE, Brazil
3 shared publications - Marcellus Henrique Loiola Ponte Souza
Federal University of Ceará
3 shared publications - David Nunes de Lima Junior
Universidade Federal do Ceará
2 shared publications - Gabriela Mie Ejima Basso
Universidade Federal do Ceará, Faculdade de Medicina, Departamento de Medicina Clínica, Serviço de Neurofisiologia Clínica, Fortaleza CE, Brazil
2 shared publications
Latest Publications
- Open Access
- 28 June 2026
- Published by Universidade Federal de Sao Paulo in Revista Neurociências
- Vol. 34, 1-22
On the prevalence of Parkinson´s Disease in patients with Inflammatory Bowel Disease
Introduction. Inflammatory bowel disease (IBD) has been associated with several neurological conditions, although its link to Parkinson's disease (PD) is controversial. Objective. To describe the prevalence and clinical findings of patients with PD in the NEURODII cohort study, initiated in 2004. Method. Clinical description, PD risk estimation, and literature review. Results. In 2023, there were 2 IBD patients with PD among 685 IBD patients (2/109 among patients with ulcerative colitis (UC) over 60 years of age). The Prevalence Ratio (PR) of PD in IBD patients, compared to the total number of PD cases in our center (438), was 1.48 (CI: 0.37-5.93, P>0.05). Compared to the highest and lowest prevalence of PD in the literature, there was no significant association between IBD and PD (PR=5.4, CI: 0.49-59.59 and 2.7, CI: 0.38-19.16, respectively P=0.16 and 0.31). A systematic review with 4 different meta-analyses supports the increased risk of PD in IBD and the decreased prevalence of IBD among patients with PD. In summary, this study is the first prospective evidence of a trend toward higher prevalence of PD in UC patients over 60 years of age (1.83%). Conclusions. Our current preliminary results do not support a definitive association between IBD and PD or that IBD accelerates the development of PD in young patients with IBD. However, our systematic review of the literature is consistent with the high risk of PD in patients with IBD. More studies are needed to confirm this association.
- 28 June 2026
- Published by Universidade Federal de Sao Paulo in Revista Neurociências
- Vol. 34, 1-22
Open AccessOn the prevalence of Parkinson´s Disease in patients with Inflammatory Bowel Disease
Introduction. Inflammatory bowel disease (IBD) has been associated with several neurological conditions, although its link to Parkinson's disease (PD) is controversial. Objective. To describe the prevalence and clinical findings of patients with PD in the NEURODII cohort study, initiated in 2004. Method. Clinical description, PD risk estimation, and literature review. Results. In 2023, there were 2 IBD patients with PD among 685 IBD patients (2/109 among patients with ulcerative colitis (UC) over 60 years of age). The Prevalence Ratio (PR) of PD in IBD patients, compared to the total number of PD cases in our center (438), was 1.48 (CI: 0.37-5.93, P>0.05). Compared to the highest and lowest prevalence of PD in the literature, there was no significant association between IBD and PD (PR=5.4, CI: 0.49-59.59 and 2.7, CI: 0.38-19.16, respectively P=0.16 and 0.31). A systematic review with 4 different meta-analyses supports the increased risk of PD in IBD and the decreased prevalence of IBD among patients with PD. In summary, this study is the first prospective evidence of a trend toward higher prevalence of PD in UC patients over 60 years of age (1.83%). Conclusions. Our current preliminary results do not support a definitive association between IBD and PD or that IBD accelerates the development of PD in young patients with IBD. However, our systematic review of the literature is consistent with the high risk of PD in patients with IBD. More studies are needed to confirm this association.
- Open Access
- 19 March 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (04) , 001-009
The prevalence of myasthenia gravis is increased in inflammatory bowel disease
Comorbid autoimmune disorders affect approximately 0.2% of the population. A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients.To evaluate the association between MG and inflammatory bowel disease (IBD).We conducted a cross-sectional study involving a Brazilian cohort of IBD patients and a literature review.In 2022, we found 1 MG patient with ulcerative colitis and 3 with Crohn's disease out of 606 IBD patients (0.66% prevalence). The patient with UC and MG died in April 2024. The mean IBD onset age was 33.5 ± 2.7; patients were 45.8 ± 7.3-years-old at evaluation. Further, 2 patients were acetylcholine receptor antibody positive, 1 was anti-muscle specific kinase positive, and 1 seronegative. Also, 3 had abnormal repetitive nerve stimulation, all had normal nerve conduction studies, abnormal skin wrinkling test, and mild small fiber neuropathy. None had thymoma and/or underwent thymectomy. According to the MG Foundation's classification, one was class V, one IVb, and two IIa. The MG diagnosis was masked by immunotherapy in all. The prevalence ratio of MG in IBD patients versus the proportion of MG among all patients in our center was 8.56 (p < 0.0001, CI = 3.1–23.5). Considering the lowest and highest prevalence of this condition reported in the literature, the ratio is 44.0 (p < 0.0001, CI: 16.3–118.4) and 26.4 (p < 0.0001, CI: 9.8–70.6), respectively.The prevalence of MG is higher in IBD, may include muscle specific kinase positive disease (first report in the literature) and frequently overlaps with other autoimmune conditions and small fiber neuropathy.
- 19 March 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (04) , 001-009
Open AccessThe prevalence of myasthenia gravis is increased in inflammatory bowel disease
Comorbid autoimmune disorders affect approximately 0.2% of the population. A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients.To evaluate the association between MG and inflammatory bowel disease (IBD).We conducted a cross-sectional study involving a Brazilian cohort of IBD patients and a literature review.In 2022, we found 1 MG patient with ulcerative colitis and 3 with Crohn's disease out of 606 IBD patients (0.66% prevalence). The patient with UC and MG died in April 2024. The mean IBD onset age was 33.5 ± 2.7; patients were 45.8 ± 7.3-years-old at evaluation. Further, 2 patients were acetylcholine receptor antibody positive, 1 was anti-muscle specific kinase positive, and 1 seronegative. Also, 3 had abnormal repetitive nerve stimulation, all had normal nerve conduction studies, abnormal skin wrinkling test, and mild small fiber neuropathy. None had thymoma and/or underwent thymectomy. According to the MG Foundation's classification, one was class V, one IVb, and two IIa. The MG diagnosis was masked by immunotherapy in all. The prevalence ratio of MG in IBD patients versus the proportion of MG among all patients in our center was 8.56 (p < 0.0001, CI = 3.1–23.5). Considering the lowest and highest prevalence of this condition reported in the literature, the ratio is 44.0 (p < 0.0001, CI: 16.3–118.4) and 26.4 (p < 0.0001, CI: 9.8–70.6), respectively.The prevalence of MG is higher in IBD, may include muscle specific kinase positive disease (first report in the literature) and frequently overlaps with other autoimmune conditions and small fiber neuropathy.
- Open Access
- 14 February 2025
- Published by Universidade Federal de Sao Paulo in Revista Neurociências
- Vol. 33, 1-18
Comportamento Hipersexual e Esclerose Múltipla
Introdução. A esclerose múltipla (EM) está associada a uma ampla gama de distúrbios comportamentais. Embora a disfunção sexual seja comum, o comportamento hipersexual é raramente relatado e tem sido frequentemente associado a comorbidades psiquiátricas. Objetivo. Realizar uma revisão sistemática dos relatos dos séculos XX e XXI sobre o comportamento hipersexual na EM. Método. Realizou-se uma revisão sistemática dos relatos de casos nos séculos XX e XXI sobre comportamento hipersexual na EM. Foram analisadas referências da era da pré-neuroimagem e da literatura mais recente com neuroimagem. A pesquisa inicial no PubMed incluiu as palavras hipersexualidade, hiperlibidinismo, parafilias, distúrbios sexuais e esclerose múltipla. Resultados. Foram encontrados sete casos relatados na literatura pré-neuroimagem e dez na era da neuroimagem, e identificadas três categorias distintas de distúrbios de acordo com a predominância dos sintomas: aumento primário da libido, desinibição e doença generalizada. A análise das lesões a partir dos estudos de neuroimagem e autópsia revelou doença do lobo frontal, periventricular e generalizada na maioria dos casos. Casos de doença disseminada apresentaram mudança abrupta do comportamento sexual e menor idade de início do acometimento. Conclusão. Em resumo, comportamento hipersexual em pacientes com EM podem ser categorizados em grupos dependendo dos sintomas e local anatômico das placas. A revisão da literatura revelou frequentemente casos com manifestações neurocomportamentais graves. O espectro leve a moderado de mudanças comportamentais pode ser subnotificado devido ao estigma social.
- 14 February 2025
- Published by Universidade Federal de Sao Paulo in Revista Neurociências
- Vol. 33, 1-18
Open AccessComportamento Hipersexual e Esclerose Múltipla
Introdução. A esclerose múltipla (EM) está associada a uma ampla gama de distúrbios comportamentais. Embora a disfunção sexual seja comum, o comportamento hipersexual é raramente relatado e tem sido frequentemente associado a comorbidades psiquiátricas. Objetivo. Realizar uma revisão sistemática dos relatos dos séculos XX e XXI sobre o comportamento hipersexual na EM. Método. Realizou-se uma revisão sistemática dos relatos de casos nos séculos XX e XXI sobre comportamento hipersexual na EM. Foram analisadas referências da era da pré-neuroimagem e da literatura mais recente com neuroimagem. A pesquisa inicial no PubMed incluiu as palavras hipersexualidade, hiperlibidinismo, parafilias, distúrbios sexuais e esclerose múltipla. Resultados. Foram encontrados sete casos relatados na literatura pré-neuroimagem e dez na era da neuroimagem, e identificadas três categorias distintas de distúrbios de acordo com a predominância dos sintomas: aumento primário da libido, desinibição e doença generalizada. A análise das lesões a partir dos estudos de neuroimagem e autópsia revelou doença do lobo frontal, periventricular e generalizada na maioria dos casos. Casos de doença disseminada apresentaram mudança abrupta do comportamento sexual e menor idade de início do acometimento. Conclusão. Em resumo, comportamento hipersexual em pacientes com EM podem ser categorizados em grupos dependendo dos sintomas e local anatômico das placas. A revisão da literatura revelou frequentemente casos com manifestações neurocomportamentais graves. O espectro leve a moderado de mudanças comportamentais pode ser subnotificado devido ao estigma social.
- 3 April 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (7) , 1225-1226
On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease
We read with interest the article written by Zamani,1 published in a recent issue of Inflammatory Bowel Diseases. It consisted of a thorough evaluation of the risk of different neurological diseases in inflammatory bowel disease (IBD). We have a few remarks about it. First, in the meta-analysis about the risk of Parkinson’s disease (PD) in IBD, the authors included 7 articles. The reference from Kang et al2 evaluates the PD risk in patients with microscopic colitis from Sweden. Microscopic colitis is usually not considered classical IBD, compromising the analysis. Among the other 6 articles from the meta-analysis, 4 (Kim,3 Lin,4 Villumsen,5 Weimers6) were large national registry studies. However, the study from Coates et al7 consisted in a retrospective cohort study from data based on “health-insurance” that included relatives as controls, thus introducing significant bias. Lastly, it is also important to highlight that the article from Park et al8 does utilize the same source (South Korean National Health Insurance Service) and experimental design (retrospective cohort) from the other article included in the meta-analysis: Kim et al.3 Since Kim et al3 is more recent and there is an overlap in time used as the inclusion criteria 2010 to 2013 for Park8 and 2011 to 2017 for Kim,3 we believe that only Kim3 should be included in the meta-analysis.
- 3 April 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (7) , 1225-1226
On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease
We read with interest the article written by Zamani,1 published in a recent issue of Inflammatory Bowel Diseases. It consisted of a thorough evaluation of the risk of different neurological diseases in inflammatory bowel disease (IBD). We have a few remarks about it. First, in the meta-analysis about the risk of Parkinson’s disease (PD) in IBD, the authors included 7 articles. The reference from Kang et al2 evaluates the PD risk in patients with microscopic colitis from Sweden. Microscopic colitis is usually not considered classical IBD, compromising the analysis. Among the other 6 articles from the meta-analysis, 4 (Kim,3 Lin,4 Villumsen,5 Weimers6) were large national registry studies. However, the study from Coates et al7 consisted in a retrospective cohort study from data based on “health-insurance” that included relatives as controls, thus introducing significant bias. Lastly, it is also important to highlight that the article from Park et al8 does utilize the same source (South Korean National Health Insurance Service) and experimental design (retrospective cohort) from the other article included in the meta-analysis: Kim et al.3 Since Kim et al3 is more recent and there is an overlap in time used as the inclusion criteria 2010 to 2013 for Park8 and 2011 to 2017 for Kim,3 we believe that only Kim3 should be included in the meta-analysis.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 61, e23134
A MEDICAL AND NEUROPSYCHIATRIC MANAGEMENT SURVEY IN A BRAZILIAN COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Inflammatory bowel disease (IBD) can be accompanied by several neurological disorders. Since 2004, we started a Brazilian cohort to assess neuropsychiatric complications in IBD patients. Changes in therapeutic strategy and differences in the prevalence and relevance of neuropsychiatric disorders have been reported in the literature. We conducted a short patient-reported survey about the medical management of IBD (with a special focus on neuropsychiatric management) and its complications. During the enrollment period (9/1/2021 to 8/31/2022), 279 patients with IBD answered the survey (128 patients with ulcerative colitis and 151 with Crohn’s disease). This is the first medical management survey aimed to verify the level of perception of IBD patients about their neuropsychiatric conditions. We found a high prevalence of neurologic (59%), psychiatric (32%), and neuropsychiatric co-morbidities (69%). There is a marked discrepancy between the findings of neurological disorders reported in our studies over the first 10 years of the cohort in comparison with the current perception/knowledge among the patients registered in the present management survey. Patients tend to have a better understanding of central rather than peripheral nerve conditions.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 61, e23134
Open AccessA MEDICAL AND NEUROPSYCHIATRIC MANAGEMENT SURVEY IN A BRAZILIAN COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Inflammatory bowel disease (IBD) can be accompanied by several neurological disorders. Since 2004, we started a Brazilian cohort to assess neuropsychiatric complications in IBD patients. Changes in therapeutic strategy and differences in the prevalence and relevance of neuropsychiatric disorders have been reported in the literature. We conducted a short patient-reported survey about the medical management of IBD (with a special focus on neuropsychiatric management) and its complications. During the enrollment period (9/1/2021 to 8/31/2022), 279 patients with IBD answered the survey (128 patients with ulcerative colitis and 151 with Crohn’s disease). This is the first medical management survey aimed to verify the level of perception of IBD patients about their neuropsychiatric conditions. We found a high prevalence of neurologic (59%), psychiatric (32%), and neuropsychiatric co-morbidities (69%). There is a marked discrepancy between the findings of neurological disorders reported in our studies over the first 10 years of the cohort in comparison with the current perception/knowledge among the patients registered in the present management survey. Patients tend to have a better understanding of central rather than peripheral nerve conditions.
- Open Access
- 30 November 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (11) , 949-955
A web-based survey to map the electromyography practice in Brazil
Background Detailed information about the electromyography practice in Brazil is largely unavailable. Objective To evaluate where and how electromyography is performed in Brazil, as well as regional disparities and the professional and academic credentials of electromyographers. Methods We conducted an internet-based survey of active Brazilian electromyographers. The websites of health insurance companies, professional academies, medical cooperatives, online search engines, and social networks in each Brazilian state were screened and we evaluated the credentials of each electromyographer listed in the Brazilian Federal Medical Board (BFMB) registration website and their online curricula vitae in the Brazilian National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, in Portuguese). We also evaluated the same parameters in a control group of non-electromyographer neurologists randomly matched by geographical distribution and gender. Results We found 469 electromyographers (384 neurologists and 85 non-neurologists), with a male predominance. In total, 81.9% were BFMB-certified neurologists, 49.9%, BFMB-certified clinical neurophysiologists, and 10.4%, BFMB-certified physiatrists. Among the non-neurologists, 48.2% were physiatrists. Most electromyographers practiced in states on the Southern and Southeastern regions of Brazil. When adjusted by population, the Federal District and the states of Mato Grosso do Sul and Goiás presented the highest of eletromyographers density. Electromyographers were not more likely to have current/past academic affiliations. Conclusion In Brazil, electromyography is performed predominantly by neurologists, and half of them are BFMB-certified clinical neurophysiologists. The present study highlights regional disparities and may guide government-based initiatives, for instance, to improve the diagnosis of leprosy and the management of neuromuscular disorders within the Brazilian territory.
- 30 November 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (11) , 949-955
Open AccessA web-based survey to map the electromyography practice in Brazil
Background Detailed information about the electromyography practice in Brazil is largely unavailable. Objective To evaluate where and how electromyography is performed in Brazil, as well as regional disparities and the professional and academic credentials of electromyographers. Methods We conducted an internet-based survey of active Brazilian electromyographers. The websites of health insurance companies, professional academies, medical cooperatives, online search engines, and social networks in each Brazilian state were screened and we evaluated the credentials of each electromyographer listed in the Brazilian Federal Medical Board (BFMB) registration website and their online curricula vitae in the Brazilian National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, in Portuguese). We also evaluated the same parameters in a control group of non-electromyographer neurologists randomly matched by geographical distribution and gender. Results We found 469 electromyographers (384 neurologists and 85 non-neurologists), with a male predominance. In total, 81.9% were BFMB-certified neurologists, 49.9%, BFMB-certified clinical neurophysiologists, and 10.4%, BFMB-certified physiatrists. Among the non-neurologists, 48.2% were physiatrists. Most electromyographers practiced in states on the Southern and Southeastern regions of Brazil. When adjusted by population, the Federal District and the states of Mato Grosso do Sul and Goiás presented the highest of eletromyographers density. Electromyographers were not more likely to have current/past academic affiliations. Conclusion In Brazil, electromyography is performed predominantly by neurologists, and half of them are BFMB-certified clinical neurophysiologists. The present study highlights regional disparities and may guide government-based initiatives, for instance, to improve the diagnosis of leprosy and the management of neuromuscular disorders within the Brazilian territory.
- Open Access
- 1 January 2023
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 45 (3) , 1-8
Tourette syndrome and multiple sclerosis: a case report
- 1 January 2023
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 45 (3) , 1-8
Open AccessTourette syndrome and multiple sclerosis: a case report
- Open Access
- 13 December 2022
- Published by Universidade Federal de Sao Paulo in Revista Neurociências
- Vol. 30, 1-8
4-Year Multiple Sclerosis Disease Remission After a Single Cycle of Alemtuzumab: a case report
Introdução. O Alemtuzumabe é um anticorpo monoclonal humanizado contra o antígeno CD52. É uma droga altamente eficaz para o tratamento da esclerose múltipla (EM) remitente recorrente. O protocolo de tratamento consiste em 2 ciclos de tratamento: 12mg/dia i.v. em infusões por 5 dias consecutivos e após um ano, infusões de 12mg/dia durante 3 dias. Até onde sabemos, há uma única série de casos na literatura detalhando a remissão da EM após um único ciclo de Alemtuzumabe. Aqui, relatamos uma experiência semelhante. Relato de caso. Uma mulher de 48 anos com fraqueza flutuante na perna direita há três anos e dor em queimação no pé direito foi diagnosticada com EM. Ela foi inicialmente tratada com Betaferon©. Sua condição progrediu e em menos de um ano, foi trocada para glatirâmer e, após novas recaídas de EM, para fingolimode. A doença progrediu para a Escala Expandida do Estado de Incapacidade (EDSS) de 7,0. Ela começou a tomar Alemtuzumabe (ciclo de cinco dias de 12mg i.v. em 6/2018). Um segundo ciclo de Alemtuzumabe não foi administrado porque ela não seguiu as diretrizes de monitoramento. Ela não desenvolveu sinais de atividade da doença após quatro anos. Conclusão. É possível que a remissão da EM seja alcançada com um único ciclo de Alemtuzumabe.
- 13 December 2022
- Published by Universidade Federal de Sao Paulo in Revista Neurociências
- Vol. 30, 1-8
Open Access4-Year Multiple Sclerosis Disease Remission After a Single Cycle of Alemtuzumab: a case report
Introdução. O Alemtuzumabe é um anticorpo monoclonal humanizado contra o antígeno CD52. É uma droga altamente eficaz para o tratamento da esclerose múltipla (EM) remitente recorrente. O protocolo de tratamento consiste em 2 ciclos de tratamento: 12mg/dia i.v. em infusões por 5 dias consecutivos e após um ano, infusões de 12mg/dia durante 3 dias. Até onde sabemos, há uma única série de casos na literatura detalhando a remissão da EM após um único ciclo de Alemtuzumabe. Aqui, relatamos uma experiência semelhante. Relato de caso. Uma mulher de 48 anos com fraqueza flutuante na perna direita há três anos e dor em queimação no pé direito foi diagnosticada com EM. Ela foi inicialmente tratada com Betaferon©. Sua condição progrediu e em menos de um ano, foi trocada para glatirâmer e, após novas recaídas de EM, para fingolimode. A doença progrediu para a Escala Expandida do Estado de Incapacidade (EDSS) de 7,0. Ela começou a tomar Alemtuzumabe (ciclo de cinco dias de 12mg i.v. em 6/2018). Um segundo ciclo de Alemtuzumabe não foi administrado porque ela não seguiu as diretrizes de monitoramento. Ela não desenvolveu sinais de atividade da doença após quatro anos. Conclusão. É possível que a remissão da EM seja alcançada com um único ciclo de Alemtuzumabe.